Project: Biosimilar For Acute Stroke Theranostic

Acronym BIOFAST (Reference Number: 11333)
Duration 04/12/2017
Project Topic Our stroke project consists in (1) producing a biosimilar to recombinant plasminogen activator (biosimilar tPa) with novel bioprocessing methods under "Good Manufacturing Practices" (GMP), (2) planning and conducting a phase I clinical study to evaluate the therapeutic. Upon success of the BIOFAST project, a final phase 1 clinical report will allow us to launch phase 3 clinical trial within 6 months of project completion.
Network Eurostars 2
Call Eurostars Cut-Off 7

Project partner

Number Name Role Country
1 Prediction BioSciences SAS Coordinator France
2 Celonic AG Partner Switzerland